Artificial intelligence (AI) and natural language processing tools can build an algorithm that identifies patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbations, ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), ...

Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

The evidence that glucose-lowering medications can improve symptoms of chronic obstructive pulmonary disease (COPD) in people with diabetes has been growing, but a few studies, including a clinical ...

The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...